Puromycin (CL13900) 2HCl

For research use only. Not for use in humans.

目录号:S7417 中文名称:嘌呤霉素盐酸盐

Puromycin (CL13900) 2HCl Chemical Structure

CAS No. 58-58-2

Puromycin 2HCl (CL13900)是一种氨基核苷抗菌素,其可作为蛋白质合成的抑制剂。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 810.81 现货
RMB 794.9 现货
RMB 2350.85 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Puromycin (CL13900) 2HCl发表文献82篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Puromycin 2HCl (CL13900)是一种氨基核苷抗菌素,其可作为蛋白质合成的抑制剂。
体外研究

抗生素puromycin由actinoniycete和Streptornyces alboniger产生,在许多体系中被用作研究蛋白质合成的工具。[1] Puromycin能够用于从非培养细胞中选择重组细胞。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmSxO|IhcA>? M12xemdzd3e2aDDpcohq[mm2aX;uJI9nKGSxeH;yeYJq[2mwLYLld4l{fGGwdDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OjZwOEOg{txONg>? NVPJVZlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
HepG2 NULQcVJXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUS3NkBp M13MPGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4zOyEQvF2u MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|MUOzNFcoRjF6M{GzN|A4RC:jPh?=
K562 NWjFbpl[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1e4blczKGh? M{fpTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIzKM7:TT6= MkLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|MUOzNFcoRjF6M{GzN|A4RC:jPh?=
HepG2 MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVi3NkBp MULHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNlEh|ryPLh?= M37BWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUGyPVg1Lz5zOEWxNlk5PDxxYU6=
Huh7 MlzPR5l1d3SxeHnjbZR6KGG|c3H5 MYjOU3ZCWlSLU{qgR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gbIVx[XSxY3XscJVt[XJiY3HyZ4lvd22jIHPlcIwhdGmwZTCoTJVpPyluIFPDOVA:Pi54MzFOwG0v M4G3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUe5O|g{Lz5zOEW3PVc5OzxxYU6=
HEK239 NXzUN5RvS3m2b4TvfIlkcXS7IHHzd4F6 MoOwO|IhcA>? NYnQcJplS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlM6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiYnz1[UBie3OjeTygTWM2OD1yLkSyJO69VS5? MknKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwOlAoRjJyNUW4NFYxRC:jPh?=
J774A1 NHzkRnVEgXSxdH;4bYNqfHliYYPzZZk> NYHZR5FiS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhUjd5NFGxJINmdGy|IHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2xNEDPxE1w NGXOO3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmzOFY{Pid-MkK5N|Q3OzZ:L3G+
KB3-1 Ml[3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3LxW|czKGi{cx?= M4D0eGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJzIN88UU4> NXTOS2lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
HepG2/Dox NFnnN5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGL2T4o4OiCqcoO= MYDHdo94fGhiaX7obYJqfGmxbjDv[kBufWy2aXTyeYchemW|aYP0ZY51KGi3bXHuJGhmeEd{L1TvfEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMkCuNkDPxE1w NI\BUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEWxNlk5PCd-MUi1NVI6QDR:L3G+
HEK293 NFTjb5dEgXSxdH;4bYNqfHliYYPzZZk> M3PBclczKGi{cx?= M3n6UmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nlicnXzZZp2emmwLXLhd4VlKHCuYYTlJJJm[WSncjDhcoFtgXOrczygTWM2OCB;IECuN|YyKM7:TT6= NF7oSIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NVU{Pyd-Mk[2OVE2Ozd:L3G+
HEK293 MlLTR5l1d3SxeHnjbZR6KGG|c3H5 M3vmZ|czKGi{cx?= NVntOYNiS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN3MEWg{txONg>? MnTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlMoRjJ5ME[wO|Y{RC:jPh?=
A549 MlG5R5l1d3SxeHnjbZR6KGG|c3H5 MmriR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3MDC9JFAvPiEQvF2u M4X3c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlE1Lz5{N{C4PVIyPDxxYU6=
PC3 Mnn4R5l1d3SxeHnjbZR6KGG|c3H5 M{LKXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{whUUN3MDC9JFAvPyEQvF2u M4PR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlE1Lz5{N{C4PVIyPDxxYU6=
HEK293 NXPJRopJS3m2b4TvfIlkcXS7IHHzd4F6 Mn22R5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE4xODB|NTFOwG0v MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJzMkC3NEc,Ojd{MUKwO|A9N2F-
HEK293 MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPSfGVjPzJiaILz NVvxSYNFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDQdoV{fG:EbIXlJJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuN|Yh|ryPLh?= M{G5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MECxNFY4Lz5{OECwNVA3PzxxYU6=
HEK293 NX7YTFY6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LXRmdzd3e2aDDpcohq[mm2aX;uJI9nKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuN|k6KM7:TT6= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRyMEKzNUc,Ojh2MECyN|E9N2F-
SU-DHL10 MXzDfZRwfG:6aXPpeJkh[XO|YYm= NX;HbYZQPzJiaILz MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUExzMDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfHKnLVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhS0N3MDC9JFAvOTFizszNMi=> M{fNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN|ExOzxxYU6=
MIAPaCa2 NFPoVoZEgXSxdH;4bYNqfHliYYPzZZk> MlGzO|IhcHK| MkL6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWlCWGGFYUKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXS{ZT3HcI8hdHWvaX7ld4NmdnRiYYPzZZktKEOFNUCgQUAxNjJizszNMi=> M1r2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN|ExOzxxYU6=
MDA-MB-231 NFXGc|dEgXSxdH;4bYNqfHliYYPzZZk> NGLaN5U4OiCqcoO= M1;yPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZZN{[XluIFPDOVAhRSByLkS4JO69VS5? MonOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkOxNFMoRjJ6NUKzNVA{RC:jPh?=
HEK293 M3ricmN6fG:2b4jpZ4l1gSCjc4PhfS=> M{fGUVczKGi{cx?= MoPnR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC52NjFOwG0v NV7WWIl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjdpPkK4O|c1PDJ5PD;hQi=>
HL60 MmjTRY51cXCjcnHzbZRq[yCjc4PhfS=> NV;5XpRjPzJiaILz NWL0[25PSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlA2PSEQvF2u MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
MOLT4 NFHVcZZCdnSrcHHyZZNqfGmlIHHzd4F6 MmryO|IhcHK| MmrTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR|UxKD1iMD6xO{DPxE1w MnfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MEOwOFcoRjJ6OECzNFQ4RC:jPh?=
Vero M{HNZmN6fG:2b4jpZ4l1gSCjc4PhfS=> M4q4UlczKGi{cx?= NIXBU3lEgXSxdH;4bYNqfHliYXfhbY5{fCCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEKuPEDPxE1w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
HEK293 NFXabHBEgXSxdH;4bYNqfHliYYPzZZk> MnvYO|IhcHK| NH;wVFFEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IILld4F7fXKrbjDkfYUh[mG|ZXSgZZN{[XluIFnDOVAhRSByLkS1JO69VS5? NFq4SHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKzOlQ6Oid-MkmyN|Y1QTJ:L3G+
HEK293T NWL3SYVFS3m2b4TvfIlkcXS7IHHzd4F6 NUjVZpRNPzJiaILz NY\IXXN6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhS0N3MDC9JFAvPDJizszNMi=> NXP3UG9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
HCT8 MVfBcpRqeGG{YYPpeIlkKGG|c3H5 MmXzOFghcHK| MVXBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDCS2YhcW6oZXP0[YQhcW5iaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBHUVSFL1TBVGkhe3SjaX7pcoch[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBGSzVyIE2gNE42PSEQvF2u NG\pPIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HCT8 M4HlXGFvfGmyYYLhd4l1cWNiYYPzZZk> NGTWVFQ1QCCqcoO= NG[wSplCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBUWExiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC54IN88UU4> NE\GZpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HepG2 M4XDSGN6fG:2b4jpZ4l1gSCjc4PhfS=> MV:3NkBpenN? MojBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gdoVi\2WwdDDiZZNm\CCudX3pcoV{[2WwY3WgZZN{[XluIFPDOVAhRSByLkizJO69VS5? NUSwSZFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
HCT8 NYDG[|VWS3m2b4TvfIlkcXS7IHHzd4F6 MnvXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVQCClZXzsd{whTUN3MDC9JFYvOSEQvF2u NWGzSpFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
HEK293 M2LKdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MmnLO|IhcHK| NIHjWnZEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTCwMlQ3KM7:TT6= M2DGW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUOzOlEyLz5{OUWzN|YyOTxxYU6=
HEK293 NVmzemtRS3m2b4TvfIlkcXS7IHHzd4F6 NUCzVI1pPzJiaILz MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISWszQTNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBlgWViYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC52IN88UU4> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl4OUK2Nkc,Ojl7NkmyOlI9N2F-
A549 Ml7XR5l1d3SxeHnjbZR6KGG|c3H5 NIrXdG81QCCqcoO= M{Ozc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE4{KM7:TT6= M4e2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEG4O|Y{Lz5|MESxPFc3OzxxYU6=
PC3 MlznR5l1d3SxeHnjbZR6KGG|c3H5 MnzYOFghcHK| NHTjOY5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE4{KM7:TT6= NXWyeIY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0NVg4PjNpPkOwOFE5PzZ|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / CDK4; 

PubMed: 31022952     


(C) Effect of puromycin on cyclin D1 and CDK4 in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4 and β actin. (D) Effect of puromycin on cyclin D1 and CDK4 in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4, and β-actin.

PARP / Bcl-xL / Bcl-2 / p-Akt / Akt; 

PubMed: 31022952     


(E) Effect of puromycin on Poly (ADP-ribose) polymerase (PARP), Bcl-xL, Bcl-2, AKT, and p-AKT (v-akt murine thymoma viral oncogene homolog) in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin. (F) Effect of puromycin on PARP, Bcl-xL, Bcl-2, AKT, and p-AKT in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL of puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin.

p53 / p21 / c-Myc; 

PubMed: 31022952     


Effect of puromycin on p53, p21, and c-Myc in a concentration and time-dependent manner in HCT116 cells. HCT116 cells were exposed to various concentrations of puromycin (0.25 or 0.5 μg/mL) for 24 h and then subjected to Western blotting with antibodies of p53, p21, and c-Myc. Also, HCT116 cells were treated with 0.5 μg/mL puromycin for 6, 12, or 24 h and subjected to Western blotting.

31022952
Growth inhibition assay
Cell viability; 

PubMed: 31022952     


Cytotoxicity of puromycin in HCT116, SW620, HCT15, and H1299 cells in a concentration-dependent manner by 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent means ± SD. *, p < 0.05, **, p < 0.01, ***, p< 0.001 vs. untreated control.

31022952

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (183.67 mM)
Water 100 mg/mL warmed (183.67 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 544.43
化学式

C22H29N7O5.2HCl

CAS号 58-58-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂
Tags: 购买Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl供应商 | 采购Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl价格 | Puromycin (CL13900) 2HCl生产 | 订购Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID